Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator

To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemical response induced by the ADA originator, after switching to them. We prospe...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Sci Rep
Asıl Yazarlar: Cingolani, Linda, Barberio, Brigida, Zingone, Fabiana, Ferronato, Antonio, Bertani, Lorenzo, Costa, Francesco, Bodini, Giorgia, Demarzo, Maria Giulia, Melatti, Piera, Gubbiotti, Alessandro, Massimi, Davide, Casadei, Cesare, D’Incà, Renata, Savarino, Edoardo Vincenzo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2021
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8121777/
https://ncbi.nlm.nih.gov/pubmed/33990652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-89790-4
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller